Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ. Schuurhuis GJ, et al. Among authors: van der reijden ba. Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Blood. 2018. PMID: 29330221 Free PMC article. Review.
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, Gottardi E, Fava M, Schnittger S, Weiss T, Izzo B, Nomdedeu J, van der Heijden A, van der Reijden BA, Jansen JH, van der Velden VH, Ommen H, Preudhomme C, Saglio G, Grimwade D. Cilloni D, et al. Among authors: van der velden vh, van der reijden ba, van der heijden a. J Clin Oncol. 2009 Nov 1;27(31):5195-201. doi: 10.1200/JCO.2009.22.4865. Epub 2009 Sep 14. J Clin Oncol. 2009. PMID: 19752335
A variant allele of Growth Factor Independence 1 (GFI1) is associated with acute myeloid leukemia.
Khandanpour C, Thiede C, Valk PJ, Sharif-Askari E, Nückel H, Lohmann D, Horsthemke B, Siffert W, Neubauer A, Grzeschik KH, Bloomfield CD, Marcucci G, Maharry K, Slovak ML, van der Reijden BA, Jansen JH, Schackert HK, Afshar K, Schnittger S, Peeters JK, Kroschinsky F, Ehninger G, Lowenberg B, Dührsen U, Möröy T. Khandanpour C, et al. Among authors: van der reijden ba. Blood. 2010 Mar 25;115(12):2462-72. doi: 10.1182/blood-2009-08-239822. Epub 2010 Jan 14. Blood. 2010. PMID: 20075157 Free PMC article.
High BRE expression predicts favorable outcome in adult acute myeloid leukemia, in particular among MLL-AF9-positive patients.
Noordermeer SM, Sanders MA, Gilissen C, Tönnissen E, van der Heijden A, Döhner K, Bullinger L, Jansen JH, Valk PJ, van der Reijden BA. Noordermeer SM, et al. Among authors: van der reijden ba, van der heijden a. Blood. 2011 Nov 17;118(20):5613-21. doi: 10.1182/blood-2011-06-359182. Epub 2011 Sep 21. Blood. 2011. PMID: 21937695 Free article.
Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies.
Kroeze LI, Nikoloski G, da Silva-Coelho P, van Hoogen P, Stevens-Linders E, Kuiper RP, Schnittger S, Haferlach T, Pahl HL, van der Reijden BA, Jansen JH. Kroeze LI, et al. Among authors: van der reijden ba, van hoogen p. Blood. 2012 Feb 2;119(5):1318-9. doi: 10.1182/blood-2011-07-365213. Blood. 2012. PMID: 22308284 Free article. No abstract available.
High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia.
Luesink M, Hollink IH, van der Velden VH, Knops RH, Boezeman JB, de Haas V, Trka J, Baruchel A, Reinhardt D, van der Reijden BA, van den Heuvel-Eibrink MM, Zwaan CM, Jansen JH. Luesink M, et al. Among authors: van der velden vh, van den heuvel eibrink mm, van der reijden ba. Blood. 2012 Sep 6;120(10):2064-75. doi: 10.1182/blood-2011-12-397083. Epub 2012 Jul 11. Blood. 2012. PMID: 22786876 Free article.
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.
Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D. Jovanovic JV, et al. Among authors: van der reijden ba. Leukemia. 2013 Oct;27(10):2032-9. doi: 10.1038/leu.2013.219. Epub 2013 Jul 17. Leukemia. 2013. PMID: 23860450 Free PMC article.
131 results